Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII

Kyowa Kirin’s NHE3 inhibitor tenapanor (KHK7791) hit its primary target, a decrease in the total number of pills from baseline, in a PII study in Japan in patients with hyperphosphatemia on hemodialysis, the company said on June 8. The primary...read more